Chiome Bioscience Inc.
4583.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.53 | 0.43 | 0.27 | -2.81 |
| FCF Yield | -6.39% | -15.99% | -15.21% | -14.40% |
| EV / EBITDA | -13.69 | -4.67 | -5.09 | -4.27 |
| Quality | ||||
| ROIC | -45.68% | -80.16% | -62.03% | -62.65% |
| Gross Margin | 55.44% | 58.41% | 55.30% | 59.26% |
| Cash Conversion Ratio | 0.98 | 0.88 | 0.96 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.37% | -1.45% | 9.47% | 16.79% |
| Free Cash Flow Growth | 6.41% | 10.23% | -5.28% | 16.83% |
| Safety | ||||
| Net Debt / EBITDA | 1.76 | 0.85 | 1.25 | 1.10 |
| Interest Coverage | -359.81 | -582.49 | -951.36 | -1,013.92 |
| Efficiency | ||||
| Inventory Turnover | 7.54 | 4.43 | 3.94 | 4.92 |
| Cash Conversion Cycle | 43.77 | 78.40 | 117.95 | 49.77 |